Quantitative PCR assays in clinical drug development

Biomarkers (biological markers) have become an integral part of both drug discovery and drug development and play an important role in the transition of potential new drugs from discovery into clinical drug development. In the past, most biomarkers were proteins/peptides and metabolites measured by technologies such as immunoassays, enzymatic assays, HPLC and mass spectrometry.

Sorry, this page is available to members only.

If you have not registered with us yet, why not register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.

Why should I register online with European Pharmaceutical Review?

You will receive . . .

* Up to date information on all latest technologies in drug development and manufacturing

* Exciting new features, interviews, updates and profiles

* All latest developments, news and innovations

* Information on projects that your industry colleagues are involved in

* Exclusive access our back issue archive

Click here to join

Login Here

Search

The Magazine

Subject Areas

Events

For Advertisers

For Authors

Quantitative PCR assays in clinical drug development